New strategy of Identifying a candidate drug of reprogramming prostate cancer by targeting gene network

2015 Fiscal Year Final Research Report

• Project/Area Number: 26861299
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Keio University
• Principal Investigator: KOSAKA TAKEO 慶應義塾大学, 医学部, 講師 (30445407)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 前立腺癌 / 幹細胞 / 薬剤耐性 / 去勢抵抗性前立腺癌 / C4-2AT6 / バイオインフォマティクス / ドラッグリポジショニング / リプログラミング療法

Outline of Final Research Achievements

Recently, new generation anti-androgen drugs and a new generation taxane, cabazitaxel have received a lot of attention as high potent agents for CRPC. However, response rate and overall survival benefit of these drugs are limited. In this study, we investigated gene expression profiles of prostate cancer using the whole human genome microarray and compared using Connectivity Map to identify candidate drugs with the potential to revert tumor’s metastatic properties.　We found a candidate drug that can possibly overcome refractory prostate cancer.

Free Research Field

前立腺癌